Developments in the treatment of gastric cancer in Europe

Metastatic gastric cancer is a relatively chemosensitive disease. With curr ent regimens, 25% to 40% of patients can be expected to respond, and median survival of 6 to 8 months is achievable. These outcomes may be improved by the use of infusional fluorouracil (5-FU) in combination with cisplatin (P latinol) or the newer agents docetaxel (Taxotere) and irinotecan (Cainptosa r). Phase II studies using these approaches have reported response rates of 50% to 60% and median survival of 11 months. Chemotherapy may also have a role in earlier stages of gastric cancer. However; the value of adjuvant th erapy ill improving survival following successful resection has still to be demonstrated, as has the survival benefit of preoperative treatment. Never theless, primary chemotherapy has demonstrated a capacity to downstage dise ase in certain otherwise inoperable cases.